<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium polystyrene sulfonate (United States: Not available): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium polystyrene sulfonate (United States: Not available): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcium polystyrene sulfonate (United States: Not available): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8498" href="/d/html/8498.html" rel="external">see "Calcium polystyrene sulfonate (United States: Not available): Drug information"</a> and <a class="drug drug_patient" data-topicid="11522" href="/d/html/11522.html" rel="external">see "Calcium polystyrene sulfonate (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52918142"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Resonium Calcium</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10540203"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span></li></ul></div>
<div class="block don drugH1Div" id="F56594380"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Each gram of resin can potentially bind up to 0.5 to 1 mEq of potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21920871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21920871'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c38c267b-5990-4874-9850-e45ba5771599">Hyperkalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, treatment: Note:</b> Due to delayed onset of action, exchange resins should not be used as emergency treatment for life-threatening hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18936701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18936701'])">Ref</a></span>). Use is contraindicated in neonates with reduced gut motility (manufacturer's labeling); generally not recommended in neonates due to low efficacy and increased risk of complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nafday.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nafday.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Rectal: 0.5 to 1 g/kg/day in divided doses every 6 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21920871','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21920871','lexi-content-ref-manu.1'])">Ref</a></span>); doses as high as 1 g/kg/dose every 6 hours have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nafday.1','lexi-content-ref-3428292']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nafday.1','lexi-content-ref-3428292'])">Ref</a></span>). Once retention time is complete, irrigate colon with NS to remove resin and prevent impaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Doherty.1','lexi-content-ref-12650312','lexi-content-ref-15001136','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Doherty.1','lexi-content-ref-12650312','lexi-content-ref-15001136','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F9647024"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Each gram of resin can potentially bind up to 0.5 to 1 mEq of potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21920871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21920871'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc1818a0-0f66-4545-a67b-d6b92f0fe2c5">Hyperkalemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia:</b> Due to delayed onset of action, exchange resins should not be used as emergency treatment for life-threatening hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18936701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18936701'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 0.5 to 1 g/kg/day in divided doses every 6 to 8 hours as needed; maximum dose: 15 g/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21920871','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21920871','lexi-content-ref-manu.1'])">Ref</a></span>); doses as high as 1 g/kg/dose have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21181208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Rectal: 0.5 to 1 g/kg/day in divided doses every 6 to 8 hours as needed; maximum dose: 30 g/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21920871','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21920871','lexi-content-ref-manu.1'])">Ref</a></span>); doses as high as 1 g/kg/dose have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21181208'])">Ref</a></span>). Once retention time is complete, irrigate the colon to ensure adequate removal of the resin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083801"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be necessary based on changes in serum potassium and/or calcium levels.</p></div>
<div class="block dohp drugH1Div" id="F51083802"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9647025"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8498" href="/d/html/8498.html" rel="external">see "Calcium polystyrene sulfonate (United States: Not available): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Each gram of resin has a theoretical in vitro exchange capacity of about 1.3 to 2 mmol (1.3 to 2 mEq) of potassium. In vivo, the actual amount of potassium bound will be less than this.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a207bfe6-1db3-4038-bf4a-7c71cccb12bf">Hyperkalemia, nonemergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia,</b>
<b>nonemergent:</b>
<b>Note: </b>Initiate treatment if serum potassium level &gt;6 mmol/L (6 mEq/L); discontinue when serum potassium level ≤5 mmol/L (5 mEq/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Usual dose: 15 g 3 to 4 times daily; dose based on clinical presentation and serum potassium level.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal enema:</b> 30 g once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990171"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be necessary based on changes in serum potassium and/or calcium levels.</p></div>
<div class="block doha drugH1Div" id="F50987516"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling</p></div>
<div class="block adr drugH1Div" id="F9646964"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Anorexia, constipation, diarrhea, gastric irritation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (Arroyo 2012), hypomagnesemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (Kao 2015), abdominal pain (Kao 2015), bezoar formation (oral administration) (Fiel 2019), fecal impaction (Fiel 2019), gastrointestinal necrosis (Joo 2009; Kao 2015), gastrointestinal stenosis, gastrointestinal ulcer (Fung 2020), ileitis (including ulcerative ileocolitis) (Mansour 2021), intestinal obstruction (Fung 2020; Kao 2015), ischemic colitis, mesenteric ischemia, peritonitis, rectal hemorrhage</p></div>
<div class="block coi drugH1Div" id="F9646937"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to polystyrene sulfonate resins or any component of the formulation; potassium &lt;5 mmol/L (5 mEq/L); conditions associated with hypercalcemia (eg, metastatic carcinoma, multiple myeloma, hyperparathyroidism, or sarcoidosis); obstructive bowel disease; oral administration in neonates; use in neonates with reduced gut motility (postoperative, drug induced)</p></div>
<div class="block war drugH1Div" id="F9646938"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte disturbances: Use may be associated with electrolyte disturbances including hypokalemia, hypercalcemia, and/or hypomagnesemia. Closely monitor electrolytes during therapy. Discontinue use if potassium ≤5 mmol/L (5 mEq/L).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Gastrointestinal stenosis, intestinal ischemia, ischemic colitis, rectal hemorrhage, gastrointestinal necrosis, and intestinal perforation with fatal outcomes have been reported, particularly in patients with underlying risk factors (eg, prematurity, history of intestinal disease or surgery, renal impairment, hypovolemia, severe burn, immunosuppressive therapy). Fecal impaction with rectal administration and concretion formation with oral administration have also occurred. Effects may be related to use of sorbitol enema with inadequate/absence of lavage after resin use. Avoid excess dosing or inadequate dilution with rectal administration to avoid resin impaction. Discontinue use in patients with clinically significant constipation. Intermittent therapy may be considered for patients developing nausea/vomiting, diarrhea, gastric irritation and anorexia, and the use of mild laxatives may be considered if constipation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in renal impairment and/or dialysis patients. Sudden increases in calcium may be observed; monitor calcium weekly (or more frequently if clinically indicated). Dosage adjustments may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates/infants: Oral administration is contraindicated in neonates. Use caution with rectal administration to avoid resin impaction. Premature/low-birth-weight infants may be at risk for GI hemorrhage or colonic necrosis.</p></div>
<div class="block prod-avail drugH1Div" id="F11217371"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block dinfoc drugH1Div" id="F52918143"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;margin-left:0em;margin-top:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for suspension, oral/rectal:</p>
<p style="text-indent:-2em;margin-left:4em;">Resonium Calcium: 300 g [contains calcium 1.6 to 2.4 mmol/g, sodium &lt;1 mg/g; packaging contains 15 g measuring device]</p></div>
<div class="block adip drugH1Div" id="F53569335"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Each 1 g of resin contains 1.6 to 2.4 mmol of calcium and &lt;1 mg of sodium.</p></div>
<div class="block admp drugH1Div" id="F52614151"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Plastic spoon provided with jar measures 15 g of powdered resin when level.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Administer orally (or via gastric tube if unable to swallow) as a suspension or paste prepared with honey, jam, water, or other liquids with low potassium content. Patients should be positioned carefully during ingestion to avoid aspiration. <b>Note:</b> Oral administration in neonates is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Rectal route is less effective than oral administration. Administer rectally as a prepared suspension; enema should be retained as long as possible, as greater amounts of potassium are excreted as retention time increases; recommended retention times: Neonates: At least 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Doherty.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Doherty.1'])">Ref</a></span>); Infants, Children, and Adolescents: At least 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21181208'])">Ref</a></span>). Once retention time is complete, irrigate colon with NS to remove resin and prevent impaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12650312','lexi-content-ref-15001136','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12650312','lexi-content-ref-15001136','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F9647027"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer orally (via nasogastric tube if unable to swallow) at least 3 hours before or 3 hours after other oral medications (patients with gastroparesis may require a 6 hour separation) as a prepared suspension or paste. Patient should be positioned carefully during ingestion to avoid aspiration. <b>Note:</b> More rapid lowering of potassium may be achieved with concomitant oral and rectal administration. Rectal route may be discontinued once orally administered resin has reached rectum.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Enema route is less effective than oral administration. Administer rectally as a prepared suspension.</p>
<p style="text-indent:-2em;margin-left:4em;">Enema should be retained as long as possible (product labeling suggests for at least 9 hours in adults or as long as possible) as greater amounts of potassium are excreted as retention time increases. Follow enema with irrigation to remove resin.<b> Note: </b>More rapid lowering of potassium may be achieved with concomitant oral and rectal administration. Rectal route may be discontinued once orally administered resin has reached rectum.</p></div>
<div class="block sts drugH1Div" id="F9646971"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53569929"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">Resonium calcium [Canadian product]: Treatment of hyperkalemia (indicated in all ages).</p></div>
<div class="block mst drugH1Div" id="F9646928"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcium polystyrene sulfonate may be confused with sodium polystyrene sulfonate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298944"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9655296"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Calcium Polystyrene Sulfonate may enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction.  Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Polystyrene Sulfonate may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, the risk for increased digoxin toxicity may occur if hypokalemia is present. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Laxatives (Magnesium Containing): May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Calcium Polystyrene Sulfonate may decrease the serum concentration of Lithium.  Management: Consider separating administration of lithium from administration of oral calcium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meloxicam: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sorbitol: May enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Calcium Polystyrene Sulfonate may decrease the serum concentration of Thyroid Products.  Management: Consider administering thyroid products at least 4 hours prior to calcium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F9646977"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May administer orally with honey, jam, or liquids with low potassium content. Do <b>not</b> mix in fruit juices (eg, orange juice) or other beverages with high potassium content. Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F9646934"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Calcium polystyrene sulfonate does not undergo gastrointestinal (GI) absorption. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block mopp drugH1Div" id="F53569859"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor serum electrolytes (potassium, sodium, calcium, magnesium); monitor for constipation; monitor for GI hemorrhage or gastric necrosis in neonates and infants.</p></div>
<div class="block pha drugH1Div" id="F9647033"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Removes potassium by exchanging calcium ions for potassium ions in the intestine before the resin is excreted from the body</p></div>
<div class="block phk drugH1Div" id="F9646972"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: May be delayed 1 to 2 days due to GI transit time</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: None</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (100%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059485"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Resincalcio</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate calcium | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Sorcal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kelassens</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium | Cps</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Resincalcio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Renostrite | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Resincalcio | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Calcium fresenius | Resikali</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium | Pebind</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Exmate | Kaliaid | Kalimate | Mitapillarin | Poscarl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Casca | Huons karos | Inist polystyrene | K down | K low | K sumer | Kalimet | Kashut | Kaska</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium | Resical</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Resincalcio | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anti Kalium | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Novefazol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Kalimate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Resincal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Calcium Resonium | Resical</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Calcium resonium | Resocal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate calcium | Sorbisterit</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Sorbisterit</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23013952">
<a name="23013952"></a>Arroyo D, Panizo N, García de Vinuesa S, Goicoechea M, Verdalles U, Luño J. Hypercalcemia as a side effect of potassium binding agents. <i>Nefrologia</i>. 2012;32(5):655-658. doi:10.3265/Nefrologia.pre2012.Jun.11500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/23013952/pubmed" id="23013952" target="_blank">23013952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B, "Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doherty.1">
<a name="Doherty.1"></a>Doherty EG. Fluid and electrolyte management. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017:chap 23.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30534857">
<a name="30534857"></a>Fiel DC, Santos I, Santos JE, et al. Cecum perforation associated with a calcium polystyrene sulfonate bezoar - a rare entity. <i>J Bras Nefrol</i>. 2019;41(3):440-444. doi:10.1590/2175-8239-JBN-2018-0158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/30534857/pubmed" id="30534857" target="_blank">30534857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31941743">
<a name="31941743"></a>Fung WW, Chi WK, Szeto CC, Li PK, Chow KM. Lessons of the month 3: duodenal perforation after polystyrene sulfonate. <i>Clin Med (Lond)</i>. 2020;20(1):107-109. doi:10.7861/clinmed.2019-0327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/31941743/pubmed" id="31941743" target="_blank">31941743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12650312">
<a name="12650312"></a>Grammatikopoulos T, Greenough A, Pallidis C, Davenport M. Benefits and risks of calcium resonium therapy in hyperkalaemic preterm infants. <i>Acta Paediatr</i>. 2003;92(1):118-120. doi:10.1111/j.1651-2227.2003.tb00481.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/12650312/pubmed" id="12650312" target="_blank">12650312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15001136">
<a name="15001136"></a>Haycock GB. Management of acute and chronic renal failure in the newborn. <i>Semin Neonatol</i>. 2003;8(4):325-334. doi:10.1016/S1084-2756(03)00044-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/15001136/pubmed" id="15001136" target="_blank">15001136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19949685">
<a name="19949685"></a>Joo M, Bae WK, Kim NH, Han SR. Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient. <i>J Korean Med Sci</i>. 2009;24(6):1207-1211. doi:10.3346/jkms.2009.24.6.1207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/19949685/pubmed" id="19949685" target="_blank">19949685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23602017">
<a name="23602017"></a>Kao CC, Tsai YC, Chiang WC, Mao TL, Kao TW. Ileum and colon perforation following peritoneal dialysis-related peritonitis and high-dose calcium polystyrene sulfonate. <i>J Formos Med Assoc</i>. 2015;114(10):1008-1010. doi:10.1016/j.jfma.2013.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/23602017/pubmed" id="23602017" target="_blank">23602017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21181208">
<a name="21181208"></a>Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384. doi:10.1007/s00467-010-1699-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/21181208/pubmed" id="21181208" target="_blank">21181208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34965050">
<a name="34965050"></a>Mansour A, Lakis A, Gallez J, Elkoulali M, Laterre E, Salame M. An unusual recurrent ileocolonic injury. <i>Acta Gastroenterol Belg</i>. 2021;84(4):666-668. doi:10.51821/84.4.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/34965050/pubmed" id="34965050" target="_blank">34965050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21920871">
<a name="21920871"></a>Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. <i>Arch Dis Child</i>. 2012;97(4):376-380. doi:10.1136/archdischild-2011-300623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/21920871/pubmed" id="21920871" target="_blank">21920871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nafday.1">
<a name="Nafday.1"></a>Nafday SM, Woda CB, Saland JM, et al. Renal disease. In: MacDonald MG, Seshia MMK, eds. <i>Avery's Neonatology: Pathophysiology and Management of the Newborn</i>. 7th ed. Wolters Kluwer; 2016:750-805.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428292">
<a name="3428292"></a>Ohlsson A, Hosking M. Complications following oral administration of exchange resins in extremely low-birth-weight infants. <i>Eur J Pediatr</i>. 1987;146(6):571-574. doi:10.1007/BF02467356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/3428292/pubmed" id="3428292" target="_blank">3428292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19751641">
<a name="19751641"></a>Resonium Calcium (calcium polystyrene sulfonate) [product monograph]. Laval, Quebec, Canada: Sanofi Aventis Canada Inc; July 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/19751641/pubmed" id="19751641" target="_blank">19751641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18936701">
<a name="18936701"></a>Weisberg LS. Management of severe hyperkalemia. <i>Crit Care Med</i>. 2008;36(12):3246-3251. doi:10.1097/CCM.0b013e31818f222b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-polystyrene-sulfonate-united-states-not-available-pediatric-drug-information/abstract-text/18936701/pubmed" id="18936701" target="_blank">18936701</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 135029 Version 14.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
